{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T13:23:09Z","timestamp":1785158589110,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2014,6,17]],"date-time":"2014-06-17T00:00:00Z","timestamp":1402963200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1007\/s11095-014-1402-7","type":"journal-article","created":{"date-parts":[[2014,6,19]],"date-time":"2014-06-19T09:58:42Z","timestamp":1403171922000},"page":"3095-3105","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Aerosolized Montelukast Polymeric Particles\u2014An Alternative to Oral Montelukast\u2013Alleviate Symptoms of Asthma in a Rodent Model"],"prefix":"10.1007","volume":"31","author":[{"given":"Brijeshkumar","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilesh","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fakhrul","family":"Ahsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,6,17]]},"reference":[{"issue":"2","key":"1402_CR1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1365-2222.2008.03157.x","volume":"39","author":"RH Dougherty","year":"2009","unstructured":"Dougherty RH, Fahy JV. Acute exacerbations of asthma: epidemiology, biology and the exacerbation-prone phenotype. Clin Exp Allergy. 2009;39(2):193\u2013202.","journal-title":"Clin Exp Allergy"},{"issue":"5","key":"1402_CR2","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1398-9995.2004.00526.x","volume":"59","author":"M Masoli","year":"2004","unstructured":"Masoli M, Fabian D, Holt S, Beasley R, Global Initiative for Asthma P. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004;59(5):469\u201378.","journal-title":"Allergy"},{"issue":"2","key":"1402_CR3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1089\/jamp.2009.0762","volume":"23","author":"M Molimard","year":"2010","unstructured":"Molimard M, Le Gros V, Robinson P, Bourdeix I. Prevalence and associated factors of oropharyngeal side effects in users of inhaled corticosteroids in a real-life setting. J Aerosol Med Pulm Drug Deliv. 2010;23(2):91\u20135.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"12","key":"1402_CR4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/01.NAJ.0000423489.90865.80","volume":"112","author":"K Rosenberg","year":"2012","unstructured":"Rosenberg K. Childhood asthma treatment can result in lower adult height: potential effect of inhaled glucocorticoids must be weighed against known benefits. Am J Nurs. 2012;112(12):14.","journal-title":"Am J Nurs"},{"issue":"10","key":"1402_CR5","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJMoa1203229","volume":"367","author":"HW Kelly","year":"2012","unstructured":"Kelly HW, Sternberg AL, Lescher R, Fuhlbrigge AL, Williams P, Zeiger RS, et al. Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med. 2012;367(10):904\u201312.","journal-title":"N Engl J Med"},{"issue":"6","key":"1402_CR6","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2500\/aap.2013.34.3700","volume":"34","author":"SB Singh","year":"2013","unstructured":"Singh SB, Weinberger MM, Zimmerman MB, Starner TD. Growth of preschool age children receiving daily inhaled corticosteroids. Allergy Asthma Proc. 2013;34(6):511\u20138.","journal-title":"Allergy Asthma Proc"},{"key":"1402_CR7","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1100\/tsw.2010.229","volume":"10","author":"GR Tintinger","year":"2010","unstructured":"Tintinger GR, Feldman C, Theron AJ, Anderson R. Montelukast: more than a cysteinyl leukotriene receptor antagonist? ScientificWorldJournal. 2010;10:2403\u201313.","journal-title":"ScientificWorldJournal"},{"issue":"11","key":"1402_CR8","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.intimp.2009.08.007","volume":"9","author":"M Muraki","year":"2009","unstructured":"Muraki M, Imbe S, Sato R, Ikeda Y, Yamagata S, Iwanaga T, et al. Inhaled montelukast inhibits cysteinyl-leukotriene-induced bronchoconstriction in ovalbumin-sensitized guinea-pigs: the potential as a new asthma medication. Int Immunopharmacol. 2009;9(11):1337\u201341.","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"1402_CR9","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3109\/02770903.2011.573042","volume":"48","author":"G Philip","year":"2011","unstructured":"Philip G, Villaran C, Shah SR, Vandormael K, Smugar SS, Reiss TF. The efficacy and tolerability of inhaled montelukast plus inhaled mometasone compared with mometasone alone in patients with chronic asthma. J Asthma. 2011;48(5):495\u2013502.","journal-title":"J Asthma"},{"issue":"3","key":"1402_CR10","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jconrel.2008.03.013","volume":"128","author":"A Rawat","year":"2008","unstructured":"Rawat A, Majumder QH, Ahsan F. Inhalable large porous microspheres of low molecular weight heparin: in vitro and in vivo evaluation. J Control Release. 2008;128(3):224\u201332.","journal-title":"J Control Release"},{"issue":"2","key":"1402_CR11","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jconrel.2012.07.003","volume":"162","author":"B Patel","year":"2012","unstructured":"Patel B, Gupta V, Ahsan F. PEG-PLGA based large porous particles for pulmonary delivery of a highly soluble drug, low molecular weight heparin. J Control Release. 2012;162(2):310\u201320.","journal-title":"J Control Release"},{"issue":"4","key":"1402_CR12","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1002\/jps.21946","volume":"99","author":"V Gupta","year":"2010","unstructured":"Gupta V, Rawat A, Ahsan F. Feasibility study of aerosolized prostaglandin E1 microspheres as a noninvasive therapy for pulmonary arterial hypertension. J Pharm Sci. 2010;99(4):1774\u201389.","journal-title":"J Pharm Sci"},{"issue":"11","key":"1402_CR13","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1023\/A:1018910200420","volume":"16","author":"R Vanbever","year":"1999","unstructured":"Vanbever R, Mintzes JD, Wang J, Nice J, Chen D, Batycky R, et al. Formulation and physical characterization of large porous particles for inhalation. Pharm Res. 1999;16(11):1735\u201342.","journal-title":"Pharm Res"},{"issue":"5","key":"1402_CR14","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ejps.2006.05.005","volume":"28","author":"F Ungaro","year":"2006","unstructured":"Ungaro F, De Rosa G, Miro A, Quaglia F, La Rotonda MI. Cyclodextrins in the production of large porous particles: development of dry powders for the sustained release of insulin to the lungs. Eur J Pharm Sci. 2006;28(5):423\u201332.","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"1402_CR15","first-page":"447","volume":"36","author":"OR Moss","year":"1979","unstructured":"Moss OR. Simulants of lung interstitial fluid. Health Phys. 1979;36(3):447\u20138.","journal-title":"Health Phys"},{"issue":"2","key":"1402_CR16","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.peptides.2012.03.021","volume":"35","author":"S Onoue","year":"2012","unstructured":"Onoue S, Matsui T, Kuriyama K, Ogawa K, Kojo Y, Mizumoto T, et al. Inhalable sustained-release formulation of long-acting vasoactive intestinal peptide derivative alleviates acute airway inflammation. Peptides. 2012;35(2):182\u20139.","journal-title":"Peptides"},{"issue":"1\u20132","key":"1402_CR17","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ijpharm.2011.03.021","volume":"410","author":"S Onoue","year":"2011","unstructured":"Onoue S, Aoki Y, Matsui T, Kojo Y, Misaka S, Mizumoto T, et al. Formulation design and in vivo evaluation of dry powder inhalation system of new vasoactive intestinal peptide derivative ([R(15, 20, 21), L(17), A(24,25), des-N(28)]-VIP-GRR) in experimental asthma\/COPD model rats. Int J Pharm. 2011;410(1\u20132):54\u201360.","journal-title":"Int J Pharm"},{"issue":"3","key":"1402_CR18","doi-asserted-by":"crossref","first-page":"L565","DOI":"10.1152\/ajplung.2001.280.3.L565","volume":"280","author":"T Glaab","year":"2001","unstructured":"Glaab T, Daser A, Braun A, Neuhaus-Steinmetz U, Fabel H, Alarie Y, et al. Tidal midexpiratory flow as a measure of airway hyperresponsiveness in allergic mice. Am J Physiol Lung Cell. 2001;280(3):L565\u201373.","journal-title":"Am J Physiol Lung Cell"},{"issue":"1\u20132","key":"1402_CR19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ijpharm.2011.04.017","volume":"413","author":"V Gupta","year":"2011","unstructured":"Gupta V, Ahsan F. Influence of PEI as a core modifying agent on PLGA microspheres of PGE(1), a pulmonary selective vasodilator. Int J Pharm. 2011;413(1\u20132):51\u201362.","journal-title":"Int J Pharm"},{"issue":"5320","key":"1402_CR20","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1126\/science.276.5320.1868","volume":"276","author":"DA Edwards","year":"1997","unstructured":"Edwards DA, Hanes J, Caponetti G, Hrkach J, Ben-Jebria A, Eskew ML, et al. Large porous particles for pulmonary drug delivery. Science. 1997;276(5320):1868\u201371.","journal-title":"Science"},{"issue":"1","key":"1402_CR21","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.peptides.2009.09.032","volume":"31","author":"S Misaka","year":"2010","unstructured":"Misaka S, Aoki Y, Karaki S, Kuwahara A, Mizumoto T, Onoue S, et al. Inhalable powder formulation of a stabilized vasoactive intestinal peptide (VIP) derivative: anti-inflammatory effect in experimental asthmatic rats. Peptides. 2010;31(1):72\u20138.","journal-title":"Peptides"},{"issue":"3\u20134","key":"1402_CR22","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ejps.2009.04.002","volume":"37","author":"S Misaka","year":"2009","unstructured":"Misaka S, Sato H, Yamauchi Y, Onoue S, Yamada S. Novel dry powder formulation of ovalbumin for development of COPD-like animal model: Physicochemical characterization and biomarker profiling in rats. Eur J Pharm Sci. 2009;37(3\u20134):469\u201376.","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"1402_CR23","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/ajcp\/52.3.320","volume":"52","author":"JH Glick Jr","year":"1969","unstructured":"Glick Jr JH. Serum lactate dehydrogenase isoenzyme and total lactate dehydrogenase values in health and disease, and clinical evaluation of these tests by means of discriminant analysis. Am J Clin Pathol. 1969;52(3):320\u20138.","journal-title":"Am J Clin Pathol"},{"issue":"8","key":"1402_CR24","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1183\/09031936.96.09081736","volume":"9","author":"M Drent","year":"1996","unstructured":"Drent M, Cobben NAM, Henderson RF, Wouters EFM, van Dieijen Visser M. Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. Eur Respir J. 1996;9(8):1736\u201342.","journal-title":"Eur Respir J"},{"issue":"1","key":"1402_CR25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.phrs.2006.02.007","volume":"54","author":"G Sener","year":"2006","unstructured":"Sener G, Sehirli O, Velioglu-Ogunc A, Cetinel S, Gedik N, Caner M, et al. Montelukast protects against renal ischemia\/reperfusion injury in rats. Pharmacol Res. 2006;54(1):65\u201371.","journal-title":"Pharmacol Res"},{"issue":"2","key":"1402_CR26","first-page":"63","volume":"3","author":"AAE Ahmed","year":"2009","unstructured":"Ahmed AAE. Protective effect of montelukast on paraquat-induced lung toxicity in rats. Biosci Trends. 2009;3(2):63\u201372.","journal-title":"Biosci Trends"},{"issue":"6","key":"1402_CR27","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0091-6749(99)70006-0","volume":"104","author":"D Ihaku","year":"1999","unstructured":"Ihaku D, Cameron L, Suzuki M, Molet S, Martin J, Hamid Q. Montelukast, a leukotriene receptor antagonist, inhibits the late airway response to allergen, airway eosinophilia, and IL-5-expressing cells in Brown Norway rats. J Allergy Clin Immunol. 1999;104(6):1147\u201354.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"1402_CR28","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1378\/chest.121.3.732","volume":"121","author":"K Minoguchi","year":"2002","unstructured":"Minoguchi K, Kohno Y, Minoguchi H, Kihara N, Sano Y, Yasuhara H, et al. Reduction of eosinophilic inflammation in the airways of patients with asthma using montelukast. Chest. 2002;121(3):732\u20138.","journal-title":"Chest"},{"issue":"Suppl 5","key":"1402_CR29","first-page":"71","volume":"60","author":"J Kosciuch","year":"2009","unstructured":"Kosciuch J, Krenke R, Gorska K, Zukowska M, Maskey-Warzechowska M, Chazan R. Relationship between airway wall thickness assessed by high-resolution computed tomography and lung function in patients with asthma and chronic obstructive pulmonary disease. J Physiol Pharmacol. 2009;60 Suppl 5:71\u20136.","journal-title":"J Physiol Pharmacol"},{"issue":"10","key":"1402_CR30","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1164\/ajrccm.164.supplement_2.2106061","volume":"164","author":"PK Jeffery","year":"2001","unstructured":"Jeffery PK. Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care. 2001;164(10):S28\u201338.","journal-title":"Am J Respir Crit Care"},{"issue":"7","key":"1402_CR31","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1164\/rccm.200501-088OC","volume":"173","author":"WR Henderson Jr","year":"2006","unstructured":"Henderson Jr WR, Chiang GK, Tien YT, Chi EY. Reversal of allergen-induced airway remodeling by CysLT1 receptor blockade. Am J Respir Crit Care Med. 2006;173(7):718\u201328.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1402_CR32","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1164\/ajrccm.165.1.2105051","volume":"165","author":"WR Henderson Jr","year":"2002","unstructured":"Henderson Jr WR, Tang LO, Chu SJ, Tsao SM, Chiang GK, Jones F, et al. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med. 2002;165(1):108\u201316.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"1402_CR33","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1164\/ajrccm.163.2.2004039","volume":"163","author":"CL Ordonez","year":"2001","unstructured":"Ordonez CL, Khashayar R, Wong HH, Ferrando R, Wu R, Hyde DM, et al. Mild and moderate asthma is associated with airway goblet cell hyperplasia and abnormalities in mucin gene expression. Am J Respir Crit Care. 2001;163(2):517\u201323.","journal-title":"Am J Respir Crit Care"},{"issue":"3","key":"1402_CR34","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jaci.2006.07.012","volume":"118","author":"DW Cockcroft","year":"2006","unstructured":"Cockcroft DW, Davis BE. Mechanisms of airway hyperresponsiveness. J Allergy Clin Immunol. 2006;118(3):551\u20139. quiz 60-1.","journal-title":"J Allergy Clin Immunol"},{"issue":"2 Suppl","key":"1402_CR35","doi-asserted-by":"crossref","first-page":"18S","DOI":"10.1378\/chest.10-0088","volume":"138","author":"DW Cockcroft","year":"2010","unstructured":"Cockcroft DW. Direct challenge tests: Airway hyperresponsiveness in asthma: its measurement and clinical significance. Chest. 2010;138(2 Suppl):18S\u201324.","journal-title":"Chest"},{"issue":"1","key":"1402_CR36","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jconrel.2010.11.001","volume":"150","author":"YJ Oh","year":"2011","unstructured":"Oh YJ, Lee J, Seo JY, Rhim T, Kim SH, Yoon HJ, et al. Preparation of budesonide-loaded porous PLGA microparticles and their therapeutic efficacy in a murine asthma model. J Control Release. 2011;150(1):56\u201362.","journal-title":"J Control Release"},{"issue":"2","key":"1402_CR37","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jconrel.2012.07.008","volume":"162","author":"A Yildiz","year":"2012","unstructured":"Yildiz A, John E, Ozsoy Y, Araman A, Birchall JC, Broadley KJ, et al. Inhaled extended-release microparticles of heparin elicit improved pulmonary pharmacodynamics against allergen-mediated airway hyper-reactivity and inflammation. J Control Release. 2012;162(2):456\u201363.","journal-title":"J Control Release"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-014-1402-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-014-1402-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-014-1402-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,11]],"date-time":"2019-08-11T18:17:15Z","timestamp":1565547435000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-014-1402-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,17]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["1402"],"URL":"https:\/\/doi.org\/10.1007\/s11095-014-1402-7","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,17]]}}}